HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, Dalekos GN.
Papatheodoridis GV, et al. Among authors: kranidioti h.
Aliment Pharmacol Ther. 2022 Aug;56(4):702-712. doi: 10.1111/apt.17093. Epub 2022 Jun 23.
Aliment Pharmacol Ther. 2022.
PMID: 35736010